{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"78.5","value":"54.1"},{"groupId":"OG001","spread":"63.1","value":"27.9"},{"groupId":"OG002","spread":"64.1","value":"33.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"38"},{"groupId":"OG002","value":"60"}],"units":"Participants"}],"description":"Predose concentration of the analyte in plasma at steady state immediately before administration of the 29th dose (Cpre,ss,29).","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Subjects receiving 30 mg of Afatinib daily.","id":"OG000","title":"Afatinib 30 mg"},{"description":"Subjects receiving 40 mg of Afatinib daily.","id":"OG001","title":"Afatinib 40 mg"},{"description":"Subjects receiving 50 mg of Afatinib daily.","id":"OG002","title":"Afatinib 50 mg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Treated Set","reportingStatus":"POSTED","timeFrame":"-0:05h (pre-dose) on Day 29","title":"Cpre,ss,29","type":"SECONDARY","unitOfMeasure":"ng/mL"}